Savolitinib Heads for Phase III Trial in PRCC.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2017-105
Abstract: A phase II trial of savolitinib, a MET inhibitor, found that the drug induced partial responses in some patients with papillary renal cell carcinoma and was well tolerated, prompting drug makers Chi-Med and AstraZeneca to… read more here.
Keywords: trial; savolitinib heads; heads phase; iii trial ... See more keywords